{"doi":"10.1007/s40123-025-01174-3","title":"Identification of a Novel Subtype of Ocular Hypertensive Eyes with the Lowest Risk of Progression Under Treatment","abstract":"INTRODUCTION: Our aim in this work is to identify a subtype of ocular hypertensive eyes that benefited the most from topical hypertensive medication. METHODS: We included 1636 patients (817 patients in the active group and 819 in the observation group) who participated in the Ocular Hypertension Treatment Study (OHTS). We developed principal component analysis (PCA), t-distributed stochastic neighbor embedding (t-SNE), and unsupervised density-based clustering, then applied to the baseline visual fields (VFs) to identify different clusters of eyes. For each cluster, the rate of mean deviation (MD) worsening was calculated based on 7 years of follow-up. To determine which cluster (subtype) of eyes responded better to the ocular hypertensive medications, MD worsening was compared between the active and observation groups within each cluster of eyes separately. RESULTS: We identified 13 clusters based on visual field (VF) tests at baseline visits. Among these, one cluster demonstrated a significantly better response to ocular hypotensive medication compared to the others. Key distinguishing characteristics of this cluster included a lower frequency of family history of glaucoma (p = 0.006) but a higher prevalence of heart disease (p < 0.001) and high blood pressure (p < 0.001). Interestingly, although eyes in this cluster had a worse baseline MD than those in all other clusters (- 2.2 ± 0.1 dB vs. + 0.47 ± 1.2 dB, p < 0.001) and patients were older (64.3 ± 9.5 vs. 54.7 ± 8.94 years, p < 0.001), this was the only cluster where the MD progression rate in the treatment (active) group was significantly lower than in the observation group (+ 0.04 dB/year vs. - 0.09 dB/year, p = 0.03). Furthermore, treated eyes in this cluster had a significantly better MD progression rate than treated eyes in all other clusters (+ 0.04 dB/year vs. - 0.07 dB/year, p < 0.001). CONCLUSIONS: We identified a subtype of ocular hypertensive eyes in the OHTS that showed a better response to topical hypotensive medications, as indicated by the least risk of progression.","journal":"Ophthalmology and Therapy","year":2025,"id":569302,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.959,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":42154,"name":"Vida Abedi","orcid":"0000-0001-7689-933X","position":1,"is_corresponding":false},{"id":391791,"name":"Xiaoqin Huang","orcid":null,"position":2,"is_corresponding":false},{"id":430866,"name":"Jiang Li","orcid":"0000-0002-7006-1285","position":3,"is_corresponding":false},{"id":1018046,"name":"Alireza Vafaei Sadr","orcid":"0000-0002-5733-6678","position":4,"is_corresponding":false},{"id":517725,"name":"Amy L. de Jongh Curry","orcid":"0000-0002-6445-2976","position":5,"is_corresponding":false},{"id":6895,"name":"Louis R. Pasquale","orcid":"0000-0002-5835-3496","position":6,"is_corresponding":false},{"id":282244,"name":"Michael V. Boland","orcid":"0000-0003-2506-7095","position":7,"is_corresponding":false},{"id":307582,"name":"Chris A. Johnson","orcid":"0000-0002-0090-630X","position":8,"is_corresponding":false},{"id":281320,"name":"Siamak Yousefi","orcid":"0000-0001-8633-5730","position":9,"is_corresponding":false},{"id":1101779,"name":"Asma Poursoroush","orcid":null,"position":0,"is_corresponding":true}],"reference_count":29,"raw_metadata":null,"created_at":"2026-07-19T02:56:59.652443Z","pmid":"40580376","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}